Evonik is sticking to its full-year outlook despite an increasingly gloomy economic environment. The company expects sales and adjusted EBITDA from continued operations to remain at least stable compared with last year. In 2018 Evonik generated – not including the divested Methacrylates business – sales of €13.3 billion and adjusted EBITDA of €2.15 billion.   In the second quarter of this year, sales declined 3% to €3.31 billion compared with the prior-year quarter. While sales volum...